logo
  

AstraZeneca : Enhertu Shows Robust And Durable Tumor Response Of 54.9% In Patients With Lung Cancer

AstraZeneca Plc. (AZN,AZN.L) and Daiichi Sankyo's HER2-directed antibody drug conjugate, Enhertu, demonstrated robust and durable tumor response of 54.9% in previously treated patients with HER2-mutant or HER2m unresectable and/or metastatic non-squamous non-small cell lung cancer or NSCLC.

Data from HER2-mutant cohort of pivotal DESTINY-Lung01 Phase II trial were presented at the European Society for Medical Oncology Congress 2021 and published in The New England Journal of Medicine.

The overall safety profile of Enhertu was consistent with previous Enhertu NSCLC trials, with no new safety signals identified.

In May 2020, ENHERTU was granted Breakthrough Therapy Designation in the US for the treatment of HER2m metastatic NSCLC.

Enhertu is being further assessed in a comprehensive clinical development program evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines is set to resume flights on its routes between the U.S. and Japan from October 30, 2002 in anticipation of easing of COVID-19-related travel restrictions, which were put in place two years ago. The airline joins American Airlines and United Airlines, who have reportedly announced the resumption of flights to Japan. Tech major Apple Inc. has asked corporate employees to return to offices at least three days a week by September 5, Bloomberg reported. The latest deadline was issued following several delays to its previous deadlines amid a resurgence in COVID-19 cases. As per the report, the company will require employees to work from offices on Tuesdays, Thursdays and a regular third day to be determined by... Retail giant Walmart reported Tuesday a net profit for the second quarter that grew 20.4 percent from last year, reflecting lower operating expenses and partially inflation driven revenue growth. The results were also driven by the rebound in international markets. Quarterly revenues topped analysts' expectations. The retailer also raised its adjusted earnings guidance for the full-year 2023.
Follow RTT